EPIDEMIOLOGY AND CLINICAL COURSE OF HIV NEPHROPATHY

HIV肾病的流行病学和临床病程

• 批准号: 6766808
• 负责人: LYNDA ANNE Marie SZCZECH
• 金额: $ 10.28万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-06-01 至 2006-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6766808
• 关键词: HIV infections; adult human (21+); clinical research; disease /disorder proneness /risk; epidemiology; human subject; kidney disorder; longitudinal human study; pathologic process; proteinuria

DESCRIPTION (adapted from the application) This proposal for career development award for Lynda Szczech, MD will provide the didactic training and research experience necessary to make her a competitive and productive clinical investigator in the field of HIV-associated nephropathy (HIVAN). This proposal focuses on the epidemiology of HIV associated nephropathy (HIVAN). HIVAN is a complication of HIV infection that is associated with a 50% annual mortality. As demonstrated by the United States Renal Data Service, HIVAN is now the fourth leading cause of end-stage renal disease in African-Americans aged 20 to 64. This study will provide vital information on the risk factors and clinical course of this kidney disease that may be used subsequently to design strategies for prevention and treatment. This study will utilize a cross-sectional survey to study a large, population-based sample of HIV-infected patients to determine the prevalence of microalbuminuria and proteinuria and the risk factors for the development of HIVAN. The cohort of patients with microalbuminuria will be followed prospectively along with a sample of patients without evidence of renal disease to determine if the presence of microalbuminuria is predictive for the development of nephropathy or other outcomes such as mortality. Determination of the natural history of microalbuminuria may subsequently provide a noninvasive means to detect early disease or predict mortality. Prevention and treatment strategies focused on patients with microalbuminuria may definitively impact the burden of disease. This proposal will also study the effect of different anti-retroviral treatment regimens and clinical markers for the progression of HIV-infection such as plasma HIV RNA level or CD4 count on the progression of nephropathy. These effects will be explored using a retrospective cohort design among the patients with evidence of nephropathy identified in the cross-sectional survey and among patients enrolled in the Women's Interagency HIV Study. This information combined with our knowledge of renal pathophysiology and the progression of kidney diseases can then be used to design effective prevention and treatment strategies aimed at decreasing the morbidity and mortality associated with this devastating nephropathy.

描述（改编自应用程序）

项目成果

Associations between CMS's Clinical Performance Measures project benchmarks, profit structure, and mortality in dialysis units.

CMS 的临床绩效衡量项目基准、利润结构和透析单位死亡率之间的关联。

• DOI: 10.1038/sj.ki.5000267
• 发表时间: 2006
• 期刊: Kidney international.
• 作者: Szczech,LA;Klassen,PS;Chua,B;Hedayati,SS;Flanigan,M;McClellan,WM;Reddan,DN;Rettig,RA;Frankenfield,DL;OwenJr,WF
• 通讯作者: OwenJr,WF

A multi-dose pharmacokinetic study of dalteparin in haemodialysis patients.

达肝素在血液透析患者中​​的多剂量药代动力学研究。

• 发表时间: 2006
• 期刊: Thrombosis and haemostasis
• 影响因子: 6.7
• 作者: Perry,StephanieL;O'Shea,SusanI;Byrne,Stephen;Szczech,LyndaA;Ortel,ThomasL
• 通讯作者: Ortel,ThomasL